This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
by Zacks Equity Research
J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.
Is Innoviva (INVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance
by Zacks Equity Research
Novo Nordisk (NVO) increases annual guidance for the year 2023 on higher sales expectations for Ozempic and Wegovy.
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy
by Zacks Equity Research
Pharma Goliath Novo Nordisk (NVO) inks collaboration agreement with Aspect Biosystems to develop and commercialize transformative cell therapy treatments for type I diabetes patients.
Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail
by Zacks Equity Research
Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.
Pfizer (PFE) Gets FDA Acceptance for Braftovi + Mektovi sNDAs
by Zacks Equity Research
FDA accepts Pfizer's (PFE) sNDAs seeking approval of Braftovi + Mektovi for BRAF V600E-mutant non-small cell lung cancer.
J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits
by Zacks Equity Research
To completely resolve its cosmetic talc litigation, J&J (JNJ) offers a settlement amount of $8.9 billion payable over a period of 25 years.
AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease
by Zacks Equity Research
CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.
Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval
by Zacks Equity Research
Novartis (NVS) receives a positive opinion from the CHMP for Entresto (sacubitril/valsartan) for a new indication in pediatric patients.
Innoviva (INVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Innoviva (INVA) closed at $13.27, marking a +0.15% move from the previous day.
Innoviva (INVA) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Innoviva (INVA) closed at $13.03, marking a -1.06% move from the previous day.
Innoviva (INVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Innoviva (INVA) closed at $13.47 in the latest trading session, marking a +1.43% move from the prior day.
Innoviva (INVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Innoviva (INVA) closed at $12.77, marking a -1.47% move from the previous day.
Did a Move to Buy Global Stocks Happen? Zacks DEC Market Strategy
by John Blank
A comprehensive look ahead to a calendar 2023 trading year that has more questions than answers at this point.
Should Value Investors Buy Innoviva (INVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights PBF Energy, Innoviva, Global Partners, Heritage-Crystal Clean and Sterling Infrastructure
by Zacks Equity Research
PBF Energy, Innoviva, Global Partners, Heritage-Crystal Clean and Sterling Infrastructure have been highlighted in this Screen of The Week article.
5 Value Stocks With Attractive EV-to-EBITDA Ratios to Snap Up
by Anindya Barman
We have screened value stocks PBF, INVA, GLP, HCCI and STRL based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
Are Investors Undervaluing Innoviva (INVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Innoviva (INVA) delivered earnings and revenue surprises of -78.18% and 81.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 0.51% and 0.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Bayer (BAYRY) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Innoviva (INVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surging Earnings Estimates Signal Upside for Innoviva (INVA) Stock
by Zacks Equity Research
Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.